Citations

Clear

55 citation(s) found for "Jentoft, Mark".

Functional Characterization of Brain Tumor-Initiating Cells and Establishment of GBM Preclinical Models that Incorporate Heterogeneity, Therapy, and Sex Differences
Garcia, César A. , Bhargav, Adip G. , Brooks, Mieu, Suárez-Meade, Paola , Mondal, Sujan Kumar , Zarco, Natanael , ReFaey, Karim , Jentoft, Mark E. , Middlebrooks, Erik H. , Carrano, Anna , Guerrero‐Cazares, Hugo , Quiñones‐Hinojosa, Alfredo , Mondal, Sujan K, Jentoft, Mark, Carrano, Anna , Guerrero-Cazares, Hugo , Schiapparelli, Paula , Sarabia-Estrada, Rachel , Middlebrooks, Erik H , Zarco, Natanael , ReFaey, Karim , Snuderl, Matija , Sarabia-Estrada, Rachel

Mayo Clinic

Molecular Cancer Therapeutics | August 31, 2021 | Volume: 20 | Issue: 12 | Pages: 2585-2597

10.1158/1535-7163.mct-20-0547 | PMID 34465594 Get It

Abstract Glioblastoma (GBM) is the most common primary brain cancer in adults where tumor cell heterogeneity and sex differences influence clinical outcomes. Here, we functionally characterize three male and three female patient-derived GBM cell lines, identify protumorigenic BTICs, and create novel male and female preclinical models of GBM. Cell lines were evaluated on the following features: proliferation, stemness, migration, tumorigenesis, clinical characteristics, and sensitivity to radiation, TMZ, rhTNFSF10 (rhTRAIL), and rhBMP4. All cell lines were classified as GBM according to epigenetic subtyping, were heterogenous and functionally distinct from one another, and re-capitulated features of the original patient tumor. In establishing male and female preclinical models, it was found that two male-derived GBM cell lines (QNS108 and QNS120) and one female-derived GBM cell line (QNS315) grew at a faster rate in female mice brains. One male-derived GBM cell line (QNS108) decreased survival in female mice in comparison with male mice. However, no survival differences were observed for mice injected with a female-derived cell line (QNS315). In summary, a panel of six GBM patient-derived cell lines were functionally characterized, and it was shown that BTIC lines can be used to construct sex-specific models with differential phenotypes for additional studies.
Influence of supramarginal resection on survival outcomes after gross-total resection of IDH–wild-type glioblastoma
Vivas-Buitrago, Tito, Domingo, Ricardo A., Tripathi, Shashwat, Biase, Gaetano De, Brown, Desmond, Akinduro, Oluwaseun O., Ramos-Fresnedo, Andres, Sabsevitz, David S., Bendok, Bernard R., Sherman, Wendy, Parney, Ian F., Jentoft, Mark E., Middlebrooks, Erik H., Meyer, Fredric B., Chaichana, Kaisorn L., Quinones-Hinojosa, Alfredo, Middlebrooks, Erik H. , Tripathi, Shashwat , Biase, Gaetano De , Sherman, Wendy , Middlebrooks, Erik H , De Biase, Gaetano , Sherman, Wendy Joyce , Vivas-Buitrago, Tito, Domingo, Ricardo A., Tripathi, Shashwat, Brown, Desmond, Akinduro, Oluwaseun O., Ramos-Fresnedo, Andres, Sabsevitz, David S., Bendok, Bernard R., Parney, Ian F., Jentoft, Mark E., Meyer, Fredric B., Chaichana, Kaisorn L., Quinones-Hinojosa, Alfredo

Mayo Clinic

Journal of Neurosurgery | June 11, 2021 | Volume: 136 | Issue: 1 | Pages: 1-8

10.3171/2020.10.jns203366 | PMID 34087795 Get It

OBJECTIVE The authors’ goal was to use a multicenter, observational cohort study to determine whether supramarginal resection (SMR) of FLAIR-hyperintense tumor beyond the contrast-enhanced (CE) area influences the overall survival (OS) of patients with isocitrate dehydrogenase–wild-type (IDH-wt) glioblastoma after gross-total resection (GTR). METHODS The medical records of 888 patients aged ≥ 18 years who underwent resection of GBM between January 2011 and December 2017 were reviewed. Volumetric measurements of the CE tumor and surrounding FLAIR-hyperintense tumor were performed, clinical variables were obtained, and associations with OS were analyzed. RESULTS In total, 101 patients with newly diagnosed IDH-wt GBM who underwent GTR of the CE tumor met the inclusion criteria. In multivariate analysis, age ≥ 65 years (HR 1.97; 95% CI 1.01–2.56; p < 0.001) and contact with the lateral ventricles (HR 1.59; 95% CI 1.13–1.78; p = 0.025) were associated with shorter OS, but preoperative Karnofsky Performance Status ≥ 70 (HR 0.47; 95% CI 0.27–0.89; p = 0.006), MGMT promotor methylation (HR 0.63; 95% CI 0.52–0.99; p = 0.044), and increased percentage of SMR (HR 0.99; 95% CI 0.98–0.99; p = 0.02) were associated with longer OS. Finally, 20% SMR was the minimum percentage associated with beneficial OS (HR 0.56; 95% CI 0.35–0.89; p = 0.01), but > 60% SMR had no significant influence (HR 0.74; 95% CI 0.45–1.21; p = 0.234). CONCLUSIONS SMR is associated with improved OS in patients with IDH-wt GBM who undergo GTR of CE tumor. At least 20% SMR of the CE tumor was associated with beneficial OS, but greater than 60% SMR had no significant influence on OS.
Non-canonical IDH Mutation Frequency in IDH1-R132H-Negative Glioblastoma Patients Older Than 54 Years
Pryzbylski, Amber L, Kollmeyer, Thomas M. , Praska, Corinne , Jentoft, Mark E. , Halling, Kevin C. , Zheng, Gang , DiGuardo, Margaret , Kipp, Benjamin R. , Jenkins, Robert B. , Praska, Corinne E, DiGuardo, Margaret A , Kollmeyer, Thomas , Pryzbylski, Amber , Raghunathan, Aditya , Giannini, Caterina , Vaubel, Rachael A. , Ida, Cristiane M.

Mayo Clinic

Journal of Neuropathology & Experimental Neurology | February 8, 2021 | Volume: 80 | Issue: 8 | Pages: 804-806

10.1093/jnen/nlab004 | PMID 33550363 Get It

Alpha 1-antichymotrypsin contributes to stem cell characteristics and enhances tumorigenicity of glioblastoma
Lara‐Velazquez, Montserrat , Zarco, Natanael , Carrano, Anna , Phillipps, Jordan, Norton, Emily S. , Schiapparelli, Paula , Al‐kharboosh, Rawan , Rincón-Torroella, Jordina , Jeanneret, Stéphanie , Corona, Teresa , Segovia, José , Jentoft, Mark E. , Chaichana, Kaisorn L. , Asmann, Yan W. , Quiñones‐Hinojosa, Alfredo , Guerrero‐Cazares, Hugo , Guerrero-Cazares, Hugo , Zarco, Natanael

Mayo Clinic

Neuro-Oncology | November 23, 2020 | Volume: 23 | Issue: 4 | Pages: 599-610

10.1093/neuonc/noaa264 | PMID 33249487 Get It

Abstract Background Glioblastomas (GBMs) are the main primary brain tumors in adults with almost 100% recurrence rate. Patients with lateral ventricle proximal GBMs (LV-GBMs) exhibit worse survival compared to distal locations for unknown reasons. One hypothesis is the proximity of these tumors to the cerebrospinal fluid (CSF) and its chemical cues that can regulate cellular phenotype. We therefore investigated the role of CSF on GBM gene expression and the role of a CSF-induced gene, SERPINA3, in GBM malignancy in vitro and in vivo. Methods We utilized human CSF and GBM brain tumor-initiating cells (BTICs). We determined the impact of SERPINA3 expression in glioma patients using The Cancer Genome Atlas (TCGA) database. SERPINA3 expression changes were evaluated at mRNA and protein levels. The effects of knockdown (KD) and overexpression (OE) of SERPINA3 on cell migration, viability and cell proliferation were evaluated. Stem cell characteristics on KD cells were evaluated by differentiation and colony formation experiments. Tumor growth was studied by intracranial and flank injections. Results GBM-CSF increased BTIC migration accompanied by upregulation of the SERPINA3 gene. In patient samples and TCGA data, we observed SERPINA3 to correlate directly with brain tumor grade and indirectly with GBM patient survival. SERPINA3 KD induced a decrease in cell proliferation, migration, invasion, and stem cell characteristics, while SERPINA3 OE increased cell migration. In vivo, SERPINA3 KD BTICs showed increased survival in a murine model. Conclusions SERPINA3 plays a key role in GBM malignancy and its inhibition results in a better outcome using GBM preclinical models.
Intracranial Myxoid Mesenchymal Tumor/Myxoid Subtype Angiomatous Fibrous Histiocytoma: Diagnostic and Prognostic Challenges
Vivas-Buitrago, Tito , Jentoft, Mark E. , Quiñones‐Hinojosa, Alfredo , Jentoft, Mark, Domingo, Ricardo A.

Mayo Clinic

Neurosurgery | September 5, 2020 | Volume: 88 | Issue: 1 | Pages: E114-E122

10.1093/neuros/nyaa357 | PMID 32970137 Get It

ABSTRACT BACKGROUND AND IMPORTANCE In the setting of intracranial neoplasms, EWSR1-cAMP Response Element-Binding Protein (CREB) transcription factor family fusions have been described in myxoid mesenchymal tumors, extremely rare entities with a close histopathologic and immunologic resemblance to myxoid subtype angiomatoid fibrous histiocytomas (AFH). Controversy exists on whether these central nervous system lesions are a subtype of myxoid AFH or a completely separate entity, which entitles a distinct clinical behavior and, consequently, a different approach to management. Upon review of the literature, only 14 cases of intracranial tumors harboring an EWSR1-CREB family fusion were identified, with only 3 cases presenting in middle-aged adults, none of which reported an EWSR1-CREM fusion mutation. Significant variability in reported radiographic and histopathological characteristics, as well as in clinical outcomes, was noted. Their similarity with other soft tissue tumors, added to the scarce information on its clinical behavior, represents a great diagnostic and therapeutic challenge to the treating physician. CLINICAL PRESENTATION We present a rare case of EWSR1-CREM mutated intracranial myxoid mesenchymal tumor/myxoid subtype AFH presenting as persistent headaches in a 36-yr-old woman with radiographic evidence of rapid growth and extensive vasogenic edema, for which she underwent surgical resection. CONCLUSION This represents a unique case of EWSR1-CREM mutated intracranial myxoid mesenchymal tumor presenting in adulthood, with evidence of aggressive behavior.
Frequency of false-positive FISH 1p/19q codeletion in adult diffuse astrocytic gliomas
Ball, Matthew K. , Kollmeyer, Thomas M. , Praska, Corinne , McKenna, Michelle L, Giannini, Caterina , Jentoft, Mark E. , Kipp, Benjamin R. , Jenkins, Robert B. , Bublitz, Michelle L. , Praska, Corinne E, Raghunathan, Aditya , Jentoft, Mark E , Jenkins, RB , Kollmeyer, Thomas , Giannini, Caterina , Raghunathan, Aditya , Lachance, Daniel Honore , Ida, Cristiane M.

Mayo Clinic

Neuro-Oncology Advances | August 27, 2020 | Volume: 2 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdaa109 | PMID 33205043 Get It

AbstractBackgroundOligodendroglioma is genetically defined by concomitant IDH (IDH1/IDH2) mutation and whole-arm 1p/19q codeletion. Codeletion of 1p/19q traditionally evaluated by fluorescence in situ hybridization (FISH) cannot distinguish partial from whole-arm 1p/19q codeletion. Partial 1p/19q codeletion called positive by FISH is diagnostically a “false-positive” result. Chromosomal microarray (CMA) discriminates partial from whole-arm 1p/19q codeletion. Herein, we aimed to estimate the frequency of partial 1p/19q codeletion that would lead to a false-positive FISH result.MethodsFISH 1p/19q codeletion test probe coordinates were mapped onto Oncoscan CMA data to determine the rate of partial 1p/19q codeletion predicted to be positive by FISH. Diffuse astrocytic gliomas with available CMA data (2015–2018) were evaluated and classified based on IDH1-R132H/ATRX/p53 immunohistochemistry, IDH/TERT promoter targeted sequencing, and/or CMA according to classification updates. Predicted false-positive cases were verified by FISH whenever possible.ResultsThe overall estimated false-positive FISH 1p/19q codeletion rate was 3.6% (8/223). Predicted false positives were verified by FISH in 6 (of 8) cases. False-positive rates did not differ significantly (P = .49) between IDH-mutant (4.6%; 4/86) and IDH-wildtype (2.9%; 4/137) tumors. IDH-wildtype false positives were all WHO grade IV, whereas IDH-mutant false positives spanned WHO grades II-IV. Testing for 1p/19q codeletion would not have been indicated for most false positives based on current classification recommendations.ConclusionSelective 1p/19q codeletion testing and cautious interpretation for conflicting FISH and histopathological findings are recommended to avoid potential misdiagnosis.
Glial Fibrillary Acidic Protein (GFAP) Autoimmunity in the Setting of Seropositive Rheumatoid Arthritis Treated With Etanercept
Amin, Shreyasee , Jentoft, Mark E. , Kantarci, Orhun H. , Smith, Kelsey M. , Jones, Lyell K. , Lachance, Daniel Honore , Flanagan, Eoin P.

Mayo Clinic

The Neurologist | September 2, 2019 | Volume: 24 | Issue: 5 | Pages: 152-154

10.1097/nrl.0000000000000243 | PMID 31478999 Get It

Introduction: Glial fibrillary acidic protein (GFAP) immunoglobulin G is a recently discovered biomarker of an autoimmune central nervous system disorder characterized by a steroid-responsive meningoencephalomyelitis. Case Report: A 63-year-old man with rheumatoid arthritis on etanercept presented with steroid-responsive subacute encephalopathy and foot drop. Brain and sural nerve biopsies demonstrated a T-cell perivascular infiltrate. Cerebrospinal fluid studies 18 months into the course of the illness demonstrated a GFAP antibody on mouse tissue immunofluorescence confirmed by cell-based assay. The patient was treated with steroids and cyclophosphamide leading to resolution of his symptoms. Conclusion: This case expands on the previously reported cases of GFAP immunoglobulin G autoimmunity by describing an associated inflammatory large fiber peripheral neuropathy.
Facial nerve venous malformation: A radiologic and histopathologic review of 11 cases
Guérin, J. , Takahashi, Edwin A. , Lane, John I. , Weindling, Steven M. , Blessing, Melissa M. , Jentoft, Mark E. , Carlson, Matthew L. , Neff, Brian A., Wood, Christopher P. , Guerin, Julie B , Hoxworth, Joseph M. , Takahashi, Edwin A

Mayo Clinic

Laryngoscope Investigative Otolaryngology | May 7, 2019 | Volume: 4 | Issue: 3 | Pages: 347-352

10.1002/lio2.267 | PMID 31236470 Get It

ObjectiveThe purpose of this article was to provide a combined pathologic and radiologic review of previous pathologically diagnosed facial nerve “hemangiomas” to confirm that these lesions are most characteristic of venous malformations rather than neoplasms.Study DesignRetrospective radiologic, clinical, and histopathologic review of all patients with a previous pathologically diagnosed facial nerve hemangioma of the temporal bone who underwent computed tomography or magnetic resonance imaging (MRI) were included. A consensus radiologic review for characteristic features and pathologic analysis was performed.Materials and MethodsA panel of 4 neuroradiologists retrospectively analyzed CT and MRI exams for 11 facial nerve hemangiomas and provided a consensus agreement on the characteristic imaging features. Concurrently, two neuropathologists reevaluated archived tissue specimens from these lesions and applied additional immunohistochemical and histochemical stains including D240, CD31, smooth muscle actin (SMA), Verhoeff Van Gieson (VVG) and glucose transporter 1 (GLUT1).ResultsLesions were composed of dilated vascular spaces with a simple, CD31‐positive endothelial lining and a smooth muscle component. All lesions were negative for markers found in arterial and lymphatic malformations and infantile hemangiomas. They had characteristic radiologic features previously ascribed to facial nerve hemangiomas. Namely, these lesions are typically T1 isointense or hypointense and T2 hyperintense relative to cerebral cortex and heterogeneously enhance on MRI. Bony canal expansion and erosion, intralesional calcification, and intracranial extension are common.ConclusionsOn the basis of this radiologic and pathologic review, these lesions are best characterized as venous malformations.Level of Evidence4
CBMT-09. ESTABLISHMENT AND IN VITRO CHARACTERIZATION OF A SPORADIC PEDIATRIC ATYPICAL MENINGIOMA CELL LINE
Kaptzan, Tatiana, Peterson, Timothy E., Jentoft, Mark E. , Brown, Desmond , Daniels, David J.

Mayo Clinic

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi34-vi34

10.1093/neuonc/noy148.128 Get It

PATH-24. RECURRENT UNUSUAL PATTERNS IN CLINICAL MOLECULAR PROFILING OF ADULT DIFFUSE GLIOMAS
Mendoza, Cinthya Zepeda, Balcom, Jessica R. , Swanson, Kirsten, Fritcher, Emily Barr, Parisi, Joseph E., Jentoft, Mark E. , Kipp, Benjamin R. , Jenkins, Robert B. , Ida, Cristiane M. , Zepeda‐Mendoza, Cinthya , Praska, Corinne , Fritcher, Emily G. Barr , Geiersbach, Katherine B. , Raghunathan, Aditya , Giannini, Caterina

Mayo Clinic

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi163-vi163

10.1093/neuonc/noy148.680 Get It